Cencora, Inc. (COR) is a $56 billion pharmaceutical distributor in Pennsylvania. Shares have outperformed the market, up 21.6% in 52 weeks and 28.7% YTD. Q3 revenue reached $80.7 billion, exceeding estimates. Analysts predict EPS growth of 15.9% for fiscal year ending September. Consensus rating is “Strong Buy” from 14 analysts.

Analyst Richard Choe maintains a “Buy” rating for COR with a $344 price target, implying a 19% upside. Mean price target is $335, a 15.9% premium. Street-high target of $355 suggests a 22.8% potential upside. Configuration is more bullish than three months ago.

Read more at Yahoo Finance: Cencora Stock: Analyst Estimates & Ratings